Loading clinical trials...
Loading clinical trials...
Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
Conditions
Interventions
Influenza A (H5N1) Virus monovalent vaccine
Saline placebo
Locations
17
United States
GSK Investigational Site
Paramount, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Newton, Kansas, United States
GSK Investigational Site
Bardstown, Kentucky, United States
GSK Investigational Site
Metairie, Louisiana, United States
GSK Investigational Site
St Louis, Missouri, United States
Start Date
March 7, 2011
Primary Completion Date
July 21, 2011
Completion Date
January 26, 2014
Last Updated
November 1, 2021
NCT01386424
NCT07291635
NCT06599658
NCT06094010
NCT06753474
NCT06417762
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions